We are hiring! Click to View Open Positions.

Posters & Presentations

June 2024

American Society of Clinical Oncology

Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase

View This Presentation

March 2024

4^th Scientific International Congress on SMA

Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy

View This Presentation

March 2024

2024 Muscular Dystrophy Association Clinical and Scientific Conference

Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review

View This Poster

March 2024

2024 Muscular Dystrophy Association Clinical and Scientific Conference

Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy

View This Poster

February 2024

Keystone Symposia: Obesity Causes and Consequences Conference

SRK-439, a Selective Anti-Pro and Latent Myostatin Antibody, Maintains Lean Mass and Enhances Fat Mass Lossin Models of Pharmacologically Induced Weight Loss

View This Poster

November 2023

Society for Immunotherapy of Cancer 2023

Safety, Efficacy, and Biomarker Results of SRK-181, a Latent TGFβ1 Inhibitor, in Anti‑PD-1 Resistant Metastatic ccRCC Patients

View This Poster